Altogether, in the era of personalized medicine, these observations can help to identify a subgroup of RA patients that could benefit from the combination of anti-RANKL therapy with a disease-modifying drug in RA management in the presence of bone loss. This evidence concerns the gene TNFSF11 and rheumatoid arthritis.